Evidence map›Paper›PMID 30558566›Full record

ArticleBMC cancer2018

Detection of mutations in SF3B1, EIF1AX and GNAQ in primary orbital melanoma by candidate gene analysis.

Anna M Rose, Rong Luo, Utsav K Radia, Helen Kalirai, Sophie Thornton, Philip J Luthert, Channa N Jayasena, David H Verity, Sarah E Coupland, Geoffrey E Rose

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Observational
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Anna M RoseOrbital Service, Moorfields Eye Hospital, City Road, London, EC1V 2PD, UK.
Rong LuoDepartment of Medicine, Imperial College, London, UK.
Utsav K RadiaDepartment of Medicine, Imperial College, London, UK.
Helen KaliraiDepartment of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
Sophie ThorntonDepartment of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
Philip J LuthertUCL Institute of Ophthalmology, London, UK.
Channa N JayasenaDepartment of Medicine, Imperial College, London, UK.
David H VerityOrbital Service, Moorfields Eye Hospital, City Road, London, EC1V 2PD, UK.
Sarah E CouplandDepartment of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
Geoffrey E RoseOrbital Service, Moorfields Eye Hospital, City Road, London, EC1V 2PD, UK. geoff.rose@moorfields.nhs.uk.
Imperial College London · GBMoorfields Eye Hospital NHS Foundation Trust · GBUniversity College London · GBUniversity of Liverpool · GBRoyal Liverpool University Hospital · GB

Funding

BRC Imperial AFPDepartment of Health PDF-2017-10-098
6 · The paper itself

Abstract

backgroundOcular melanoma is a rare but often deadly malignancy that arises in the uvea (commonest primary site), conjunctiva or the orbit. Primary orbital melanoma (POM) is exceedingly rare, with approximately 60 cases reported to date. Despite recent advances in our understanding of the genetics of primary uveal and conjunctival melanomas, this information is lacking for POM.

methodsDNA was extracted from 12 POM tissues, with matched germline DNA (where available). MLPA was conducted to detect chromosomal alterations and Sanger sequencing used to identify point mutations in candidate melanoma driver genes (BRAF, NRAS, KRAS, GNA11, GNAQ), and other genes implicated in melanoma prognosis (EIF1AX, SF3B1). Immunohistochemistry was performed to analyse BAP1 nuclear expression.

resultsMLPA detected copy number alterations in chromosomes 1p, 3, 6 and 8. Sequencing of melanoma driver genes revealed GNAQ (p.Q209L) mutations in two samples; although it is possible that these samples represent extraocular spread of an occult uveal melanoma. A recurrent mutation in SF3B1 (p.R625H) was observed in indolent, but not aggressive, tumours; a mutation in EIF1AX (p.N4S) was detected in one patient with non-aggressive disease.

conclusionsEIF1AX and SF3B1 mutations appear have a role in determining the clinical course of POM and detection of these changes could have clinical significance. Further in depth analysis of this rare group using differing 'omic technologies will provide novel insights into tumour pathogenesis.

Indexed as

MutationAdultAgedAged, 80 and overChromosomes, Human, Pair 1Chromosomes, Human, Pair 3Chromosomes, Human, Pair 6Chromosomes, Human, Pair 8DNA Copy Number VariationsEukaryotic Initiation Factor-1FemaleGTP-Binding Protein alpha Subunits, Gq-G11HumansMaleMelanomaMiddle AgedEukaryotic Initiation Factor-1eukaryotic peptide initiation factor-1AGNAQ protein, humanGTP-Binding Protein alpha Subunits, Gq-G11PhosphoproteinsRNA Splicing FactorsSF3B1 protein, humanEIF1AXMelanomaOrbitPrimarySF3B1

Identifiers

PMID30558566
PMCPMC6297940
OpenAlexW2905587928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.